<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04270344</url>
  </required_header>
  <id_info>
    <org_study_id>JW-PTVV-01</org_study_id>
    <nct_id>NCT04270344</nct_id>
  </id_info>
  <brief_title>The Occurrence of MACE in Patients With AMI Receiving Pitavastatin/Valsartan Treatment</brief_title>
  <acronym>LAMISIII</acronym>
  <official_title>A 12-month Open-label, Multicenter Observation Study on the Occurrence of Major Adverse Cardiac Events (MACE) in Patients With Acute Myocardial Infarction (AMI) Receiving Pitavastatin/Valsartan Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JW Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JW Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective Observation study to identify the rate of MACE in AMI with Livalo
      V(Pitavastatin/Valsartan) for 12 month in Korea
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following subjects with AMI event within 1 month will be assessed MACE event for 1year

        -  Essential hypertension or heart failure

        -  Idiopathic hypercholesterolemia (heterogeneous familial and non-familial
           hypercholesterolemia, Fredrickson classification type IIa)

        -  Mixed-type hypercholesterolemia (Fredrickson classification type IIb) with acute
           myocardial infarction (STEMI, NSTEMI),
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>all-cause mortality, non-fatal MI, repeat re-vascularization</measure>
    <time_frame>12 months</time_frame>
    <description>MACE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of mortality</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>MACE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of cardiac death</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>MACE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of nonfatal MI</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>MACE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of hospitalization due to heart failure</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>MACE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of Coronary artery bypass graft(CABG)</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>MACE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of target lesion re-vascularization</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>MACE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of target vessel re-vascularization</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>MACE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of cerebrovascular disease</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>MACE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of SBP, DBP</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Hypertensive parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of TC, TG, HDL-C, LDL-C, hsCRP</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Lipid parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of HbA1c, FBS</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>No Onset of Diabetes</description>
  </secondary_outcome>
  <enrollment type="Anticipated">905</enrollment>
  <condition>Hypercholesterolemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pitavastatin 4mg</intervention_name>
    <description>combination therapy with pitavastatin/valsartan (LivaloV)</description>
    <other_name>valsartan</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        hypercholesterolemia and AMI
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  idiopathic hypercholesterolemia (heterogeneous familial and non-familial, Fredrickson
             type IIa) or mixed-type (Fredrickson type IIb) with AMI (STEMI, NSTEMI), including
             essential hypertension or heart failure

          -  diagnosed AMI (STEMI, NSTEMI) 1 months ago

          -  more than 19 years old and more than 2 years of life expectancy at screening

          -  informed consent

        Exclusion Criteria:

          -  cardiogenic shock or corresponding clinical events

          -  contraindicated to the IP

          -  unsuitable to this study judged by investigators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myungho Jeong, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Chonnam National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Myungho Jeong, Professor</last_name>
    <phone>82-62-220-6243</phone>
    <email>myungho@chol.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>JWP</name>
      <address>
        <city>Seoul</city>
        <state>Seocho-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>KIM HJ</last_name>
      <phone>82-2-840-6802</phone>
      <email>hjkim@jw-pharma.co.kr</email>
    </contact>
    <investigator>
      <last_name>Jeong Myung Ho, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 12, 2020</study_first_submitted>
  <study_first_submitted_qc>February 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2020</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Pitavastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

